Other Events ·
Northwest Biotherapeutics addressed rumors alleging that the Medicines and Healthcare Products Regulatory Agency…
NWBONorthwest Biotherapeutics Inc
Northwest Biotherapeutics addressed rumors alleging that the Medicines and Healthcare Products Regulatory Agency (MHRA) rejected its Marketing Authorization Application (MAA) for DCVax-L for glioblastoma (GBM). The MHRA confirmed the application remains under initial regulatory review and has not been refused, withdrawn, or appealed. The company refutes the rumors and suggests they may be part of stock manipulation following the presentation of encouraging Phase 3 trial data at the British Neuro-Oncology Society Annual Meeting. Northwest Biotherapeutics is a biotechnology company developing cancer immunotherapies.